Embrace Progress

@article{Bradley2018EmbraceP,
  title={Embrace Progress},
  author={Kevin M. Bradley and Daniel R. McGowan and Fergus V Gleeson and Geoffrey B. Johnson and Jason R. Young and Craig S. Levin and Guido A. Davidzon and Andrei H. Iagaru},
  journal={The Journal of Nuclear Medicine},
  year={2018},
  volume={59},
  pages={1169 - 1169}
}
TO THE EDITOR: We would like to comment on the letters by Boellaard et al. in this issue of The Journal of Nuclear Medicine and Barrington et al. (1). The authors urge reporters not to use PET reconstruction algorithms, which exploit point-spread function (PSF) modeling or Bayesian penalized likelihood (BPL) techniques for response assessment in lymphoma. This call to ignore a more sensitive reconstruction technique, demonstrated to yield image data closer to phantom truth (2), and with the… 
New PET technologies – embracing progress and pushing the limits
Thanks to companies’ research and development processes, frequently involving fruitful partnerships with academic centres, and what could be acknowledged as welcome competition between PET vendors,

References

SHOWING 1-6 OF 6 REFERENCES
All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting
TLDR
An increase in the number of patients with interim PET ‘positive’ scans being treated by a regional haematology multidisciplinary team for Hodgkin lymphoma in the UK coincided with the adoption of Q.Clear (GE) reconstruction for reporting scans at some PET centres, and an independent review of PET-CT scans from eight patients with advanced stage disease was undertaken.
Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
TLDR
Neither DS nor risk stratification of diffuse large B-cell lymphoma patients is affected by the choice of PET reconstruction, and the use of PSF is not an issue in routine clinical processes or in multicenter trials.
Phantom and Clinical Evaluation of the Bayesian Penalized Likelihood Reconstruction Algorithm Q.Clear on an LYSO PET/CT System
TLDR
The optimum penalization factor (beta) for clinical use of Q.Clear is determined and improved CR and reduced BV is demonstrated when using Q. clear instead of OSEM.
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
TLDR
Quantitative methods to perform PET in standardized ways have also been developed which may further improve response assessment including a quantitative extension to the DC (qPET), which may have advantages in providing a continuous scale to refine the threshold for adequate/inadequate response in specific clinical situations or treatment optimization in trials.
Effect of a Bayesian Penalized Likelihood PET Reconstruction Compared With Ordered Subset Expectation Maximization on Clinical Image Quality Over a Wide Range of Patient Weights.
TLDR
BPL provides a more consistent visually assessed image quality and liver background SNR than does OSEM, with the greatest benefit for the heaviest patients.
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B‐cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group‐37 study
The International Extranodal Lymphoma Study Group (IELSG)‐37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with